Mass Balance Study
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
InventisBioChina - Shanghai
2 programs2
[14C] D-1553Phase 11 trial
[14C] D-2570 groupPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
InventisBio[14C] D-2570 group
Hutchmed100 µCi [14C] HMPL-306
InventisBio[14C] D-1553
Clinical Trials (3)
Total enrollment: 22 patients across 3 trials
Mass Balance Study of [14C] D-2570
Start: Mar 2026Est. completion: Apr 20268 patients
Phase 1Not Yet Recruiting
Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
Start: Nov 2024Est. completion: Jul 20256 patients
Phase 1Completed
Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects
Start: Dec 2023Est. completion: Jan 20248 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.